Clinical Trial Update: A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED) [Phase 1]

View source ↗

Summary

A completed Phase 1 study in type 2 diabetes evaluated the effects of extended-release niacin and laropiprant (alone and in combination) versus placebo on urina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ER Niacin (extended-release niacin)
• ER Niacin/Laropiprant (extended-release niacin and laropiprant combination)
• Laropiprant (laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2009-02-05